St. Louis, MO, United States of America

Jacob Myerson


 

Average Co-Inventor Count = 2.7

ph-index = 2

Forward Citations = 9(Granted Patents)


Company Filing History:


Years Active: 2017

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations of Jacob Myerson

Introduction

Jacob Myerson is an accomplished inventor based in St. Louis, MO (US). He has made significant contributions to the field of medical technology, particularly in the development of antithrombotic nanoparticles. With a total of two patents to his name, Myerson's work is paving the way for advancements in healthcare.

Latest Patents

Myerson's latest patents include an innovative antithrombotic nanoparticle. This invention encompasses a unique nanoparticle designed to prevent thrombus formation, which is crucial in treating various cardiovascular conditions. The second patent also focuses on the same antithrombotic nanoparticle, emphasizing its potential applications in medical treatments.

Career Highlights

Jacob Myerson is affiliated with Washington University, where he conducts research and develops his inventions. His work is recognized for its potential impact on patient care and treatment methodologies. Myerson's dedication to innovation in the medical field is evident through his research and patent filings.

Collaborations

Myerson collaborates with notable colleagues, including Samuel A. Wickline and Rohun Palekar. These partnerships enhance the research and development process, allowing for a more comprehensive approach to innovation in medical technology.

Conclusion

Jacob Myerson's contributions to the field of antithrombotic nanoparticles highlight his role as a significant inventor in medical technology. His work at Washington University and his collaborations with esteemed colleagues further underscore his commitment to advancing healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…